Amedeo Smart

Free Medical Literature Service



Liver Diseases

  Free Subscription

Articles published in
Int J Cancer
    July 2021
  1. CAO M, Huang W, Chen Y, Li G, et al
    Chronic restraint stress promotes the mobilization and recruitment of myeloid-derived suppressor cells through beta-adrenergic-activated CXCL5-CXCR2-Erk signaling cascades.
    Int J Cancer. 2021;149:460-472.
    >> Share

  2. ZHUO Z, Miao L, Hua W, Chen H, et al
    Genetic variations in nucleotide excision repair (NER) pathway genes and hepatoblastoma susceptibility.
    Int J Cancer. 2021 Jul 1. doi: 10.1002/ijc.33722.
    >> Share

    June 2021
  3. WANG L, Long J, Chen H, Sun S, et al
    Manipulation of focal Wnt activity via synthetic cells in a double-humanized zebrafish model of tumorigenesis.
    Int J Cancer. 2021;148:2815-2824.
    >> Share

    May 2021
  4. LONG L, Liu X, Jin L, Simon T, et al
    Association of bowel movement frequency and laxative use with risk of hepatocellular carcinoma in US women and men.
    Int J Cancer. 2021 May 24. doi: 10.1002/ijc.33699.
    >> Share

    April 2021
  5. MAYEN AL, Aglago EK, Knaze V, Cordova R, et al
    Dietary intake of advanced glycation endproducts and risk of hepatobiliary cancers: a multinational cohort study.
    Int J Cancer. 2021 Apr 25. doi: 10.1002/ijc.33612.
    >> Share

  6. LU L, Xing K, Wei W, Ling Y, et al
    Immune-related adverse events predict responses to PD-1 blockade immunotherapy in hepatocellular carcinoma.
    Int J Cancer. 2021 Apr 22. doi: 10.1002/ijc.33609.
    >> Share

  7. ZHU HB, Xu D, Ye M, Sun L, et al
    Deep learning-assisted magnetic resonance imaging prediction of tumor response to chemotherapy in patients with colorectal liver metastases.
    Int J Cancer. 2021;148:1717-1730.
    >> Share

    March 2021
  8. HUANG C, Fang M, Feng H, Liu L, et al
    N-glycan fingerprint predicts alpha-fetoprotein negative hepatocellular carcinoma: a large-scale multicenter study.
    Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33564.
    >> Share

  9. MORISUE R, Kojima M, Suzuki T, Nakatsura T, et al
    Sarcomatoid Hepatocellular Carcinoma is Distinct from Ordinary Hepatocellular Carcinoma: Clinicopathologic, Transcriptomic, and Immunologic Analyses.
    Int J Cancer. 2021 Mar 4. doi: 10.1002/ijc.33545.
    >> Share

  10. WASHINGTON MK, Goldberg RM, Chang GJ, Limburg P, et al
    Diagnosis of digestive system tumours.
    Int J Cancer. 2021;148:1040-1050.
    >> Share

    February 2021
  11. WANG XH, Liu QB, Xiang CL, Mao XH, et al
    Multi-institutional validation of novel models for predicting the prognosis of patients with huge hepatocellular carcinoma.
    Int J Cancer. 2021 Feb 14. doi: 10.1002/ijc.33516.
    >> Share

  12. XUE M, Lin X, Lin QX, Pu X, et al
    Association between Hepatitis B and E virus infection and hepatocellular carcinoma risk.
    Int J Cancer. 2021 Feb 7. doi: 10.1002/ijc.33505.
    >> Share

    November 2020
  13. WEI R, Zhu WW, Yu GY, Wang X, et al
    S100 calcium-binding protein A9 from tumor-associated macrophage enhances cancer stem cell-like properties of hepatocellular carcinoma.
    Int J Cancer. 2020 Nov 17. doi: 10.1002/ijc.33371.
    >> Share

  14. HEO MJ, Kang SH, Kim YS, Lee JM, et al
    UBC12-mediated SREBP-1 neddylation worsens metastatic tumor prognosis.
    Int J Cancer. 2020;147:2550-2563.
    >> Share

  15. CHENG C, Zhao Y, Schaafsma E, Weng YL, et al
    An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.
    Int J Cancer. 2020;147:2621-2633.
    >> Share

    October 2020
  16. LUU HN, Neelakantan N, Geng TT, Wang R, et al
    Quality diet indexes and risk of hepatocellular carcinoma: Findings from the Singapore Chinese Health Study.
    Int J Cancer. 2020 Oct 31. doi: 10.1002/ijc.33367.
    >> Share

  17. THURMAIER J, Heinemann V, Engel J, Schubert-Fritschle G, et al
    Patients with colorectal cancer and brain metastasis: The relevance of extracranial metastatic patterns predicting time intervals to first occurrence of intracranial metastasis and survival.
    Int J Cancer. 2020 Oct 28. doi: 10.1002/ijc.33364.
    >> Share

  18. SCHLICKER A, Ellappalayam A, Beumer IJ, Snel MHJ, et al
    Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis.
    Int J Cancer. 2020;147:2303-2315.
    >> Share

  19. GERMANOVA D, Keirsse J, Kohler A, Hastir JF, et al
    Myeloid TNF and HO-1 regulate the progression of colorectal liver metastases during hepatic ischemia-reperfusion.
    Int J Cancer. 2020 Oct 10. doi: 10.1002/ijc.33334.
    >> Share

    September 2020
  20. HWANG S, Park YM, Han KD, Yun JS, et al
    Associations of General Obesity and Central Obesity with the Risk of Hepatocellular Carcinoma in a Korean Population: A National Population-Based Cohort Study.
    Int J Cancer. 2020 Sep 21. doi: 10.1002/ijc.33305.
    >> Share

  21. FRENCH B, Sadakane A, Cologne J, Mabuchi K, et al
    Misclassification of primary liver cancer in the Life Span Study of atomic bomb survivors.
    Int J Cancer. 2020;147:1294-1299.
    >> Share

  22. GIANNINI V, Rosati S, Defeudis A, Balestra G, et al
    Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy.
    Int J Cancer. 2020 Sep 1. doi: 10.1002/ijc.33271.
    >> Share

    August 2020
  23. ZHONG GC, Wang K, Peng Y, Shivappa N, et al
    Dietary inflammatory index and incidence of and death from primary liver cancer: A prospective study of 103,902 American adults.
    Int J Cancer. 2020;147:1050-1058.
    >> Share

  24. FLORIO AA, Campbell PT, Zhang X, Zeleniuch-Jacquotte A, et al
    Abdominal and gluteofemoral size and risk of liver cancer: The liver cancer pooling project.
    Int J Cancer. 2020;147:675-685.
    >> Share

    July 2020
  25. STEPIEN M, Keski-Rahkonen P, Kiss A, Robinot N, et al
    Metabolic perturbations prior to hepatocellular carcinoma diagnosis - Findings from a prospective observational cohort study.
    Int J Cancer. 2020 Jul 31. doi: 10.1002/ijc.33236.
    >> Share

  26. HASSAN SA, Schmithals C, von Harten M, Piiper A, et al
    Time-dependent changes in proliferation, DNA damage and clock gene expression in hepatocellular carcinoma and normal liver of a transgenic mouse model.
    Int J Cancer. 2020 Jul 23. doi: 10.1002/ijc.33228.
    >> Share

  27. LINDNER AU, Carberry S, Monsefi N, Barat A, et al
    Systems analysis of protein signatures predicting Cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenografts models of metastatic colorectal cancer.
    Int J Cancer. 2020 Jul 23. doi: 10.1002/ijc.33226.
    >> Share

  28. ZHAO L, Zhang X
    Comments on "One-Carbon Metabolism-Related Micronutrients Intake and Risk for Hepatocellular Carcinoma: A Prospective Cohort Study".
    Int J Cancer. 2020 Jul 4. doi: 10.1002/ijc.33184.
    >> Share

  29. ANTWI SO
    Reply to Comments on "One-Carbon Metabolism-Related Micronutrients Intake and Risk for Hepatocellular Carcinoma: A Prospective Cohort Study".
    Int J Cancer. 2020 Jul 4. doi: 10.1002/ijc.33186.
    >> Share

    June 2020
  30. OKADA R, Otsuka Y, Wakabayashi T, Shinoda M, et al
    Six autoantibodies as potential serum biomarkers of hepatocellular carcinoma: a prospective multicenter study.
    Int J Cancer. 2020 Jun 23. doi: 10.1002/ijc.33165.
    >> Share

    May 2020
  31. GHOSH S, Bhowmik S, Majumdar S, Goswami A, et al
    The Exosome Encapsulated microRNAs as Circulating Diagnostic Marker for Hepatocellular Carcinoma with Low Alpha fetoprotein.
    Int J Cancer. 2020 May 22. doi: 10.1002/ijc.33111.
    >> Share

  32. PETRICK JL, Florio AA, Koshiol J, Pfeiffer RM, et al
    Prediagnostic Concentrations of Circulating Bile Acids and Hepatocellular Carcinoma Risk: REVEAL-HBV and HCV Studies.
    Int J Cancer. 2020 May 13. doi: 10.1002/ijc.33051.
    >> Share

    April 2020
  33. ANTWI SO, Petrick JL, Campbell PT, Norez DA, et al
    One-Carbon Metabolism-Related Micronutrients Intake and Risk for Hepatocellular Carcinoma: A Prospective Cohort Study.
    Int J Cancer. 2020 Apr 14. doi: 10.1002/ijc.33007.
    >> Share

    March 2020
  34. TAK KY, Nam HC, Choi JY, Yoon SK, et al
    Effectiveness of Sorafenib Dose Modifications on Treatment Outcome of Hepatocellular Carcinoma: Analysis in Real-Life Settings.
    Int J Cancer. 2020 Mar 13. doi: 10.1002/ijc.32964.
    >> Share

  35. JUENGPANICH S, Topatana W, Lu C, Staiculescu D, et al
    Role of Cellular, Molecular, and Tumor Microenvironment in Hepatocellular Carcinoma: Possible Targets and Future Directions in the Regorafenib Era.
    Int J Cancer. 2020 Mar 12. doi: 10.1002/ijc.32970.
    >> Share

  36. TRAN KT, McMenamin UC, Coleman HG, Cardwell CR, et al
    Statin use and risk of liver cancer: Evidence from two population-based studies.
    Int J Cancer. 2020;146:1250-1260.
    >> Share

  37. STRIJKER M, Soer EC, de Pastena M, Creemers A, et al
    Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.
    Int J Cancer. 2020;146:1445-1456.
    >> Share

  38. KHARE T, Khare S, Angdisen JJ, Zhang Q, et al
    Defects in long chain 3-hydroxy acyl-CoA dehydrogenase lead to hepatocellular carcinoma: A novel etiology of hepatocellular carcinoma.
    Int J Cancer. 2020 Mar 1. doi: 10.1002/ijc.32943.
    >> Share

    February 2020
  39. ZHONG GC, Peng Y, Wang K, Wan L, et al
    Magnesium intake and primary liver cancer incidence and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2020 Feb 27. doi: 10.1002/ijc.32939.
    >> Share

  40. RUAN Q, Wang H, Burke LJ, Bridle KR, et al
    Therapeutic modulators of hepatic stellate cells for hepatocellular carcinoma.
    Int J Cancer. 2020 Feb 3. doi: 10.1002/ijc.32899.
    >> Share

  41. XIAO Q, Zhou Y, Winter S, Buttner F, et al
    Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients.
    Int J Cancer. 2020 Feb 3. doi: 10.1002/ijc.32898.
    >> Share

    January 2020
  42. TRICKEY A, May MT, Gill MJ, Grabar S, et al
    Cause-specific mortality after diagnosis of cancer among HIV-positive patients: a collaborative analysis of cohort studies.
    Int J Cancer. 2020 Jan 31. doi: 10.1002/ijc.32895.
    >> Share

  43. HAGGSTROM C, Jonsson H, Bjorge T, Nagel G, et al
    Linear age-course effects on the associations between body mass index, triglycerides, and female breast and male liver cancer risk: An internal replication study of 800,000 individuals.
    Int J Cancer. 2020;146:58-67.
    >> Share

    December 2019
  44. ABRAHAMSSON H, Jensen BV, Berven LL, Nielsen DL, et al
    Antitumour immunity invoked by hepatic arterial infusion of first-line oxaliplatin predicts durable colorectal cancer control after liver metastasis ablation; 8-12 years of follow-up.
    Int J Cancer. 2019 Dec 24. doi: 10.1002/ijc.32847.
    >> Share

  45. WOLSTENHOLME J, Fusco F, Gray AM, Moschandreas J, et al
    Quality of life in the FOXFIRE, SIRFLOX, and FOXFIRE-Global randomised trials of selective internal radiotherapy for metastatic colorectal cancer.
    Int J Cancer. 2019 Dec 16. doi: 10.1002/ijc.32828.
    >> Share

    November 2019
  46. IIOKA H, Saito K, Sakaguchi M, Tachibana T, et al
    Crumbs3 is a critical factor that regulates invasion and metastasis of colon adenocarcinoma via the specific interaction with FGFR1.
    Int J Cancer. 2019;145:2740-2753.
    >> Share

  47. MELLO T, Materozzi M, Zanieri F, Simeone I, et al
    Liver haploinsufficiency of RuvBL1 causes hepatic insulin resistance and enhances hepatocellular carcinoma progression.
    Int J Cancer. 2019 Nov 12. doi: 10.1002/ijc.32787.
    >> Share

  48. ENGEL LS, Zabor EC, Satagopan J, Widell A, et al
    Prediagnostic serum organochlorine insecticide concentrations and primary liver cancer: A case-control study nested within two prospective cohorts.
    Int J Cancer. 2019;145:2360-2371.
    >> Share

    October 2019
  49. PETRICK JL, Florio AA, Znaor A, Ruggieri D, et al
    International trends in hepatocellular carcinoma incidence, 1978-2012.
    Int J Cancer. 2019 Oct 9. doi: 10.1002/ijc.32723.
    >> Share

  50. UMEDA S, Kanda M, Miwa T, Tanaka H, et al
    Fraser extracellular matrix complex subunit 1 promotes liver metastasis of gastric cancer.
    Int J Cancer. 2019 Oct 9. doi: 10.1002/ijc.32705.
    >> Share

  51. LAI SW
    Statins use and risk of liver cancer.
    Int J Cancer. 2019;145:2008.
    >> Share

  52. TRAN KT, Cardwell CR, Thrift AP
    Authors' reply to: Statin use and risk of liver cancer.
    Int J Cancer. 2019;145:2009.
    >> Share

    September 2019
  53. MIZUKOSHI K, Okazawa Y, Haeno H, Koyama Y, et al
    Metastatic seeding of human colon cancer cell clusters expressing the hybrid epithelial/mesenchymal state.
    Int J Cancer. 2019 Sep 10. doi: 10.1002/ijc.32672.
    >> Share

  54. PANG Y, Kartsonaki C, Guo Y, Chen Y, et al
    Central adiposity in relation to risk of liver cancer in Chinese adults: A prospective study of 0.5 million people.
    Int J Cancer. 2019;145:1245-1253.
    >> Share

    August 2019
  55. YU J, Ding WB, Wang MC, Guo XG, et al
    Plasma Circular RNA Panel to Diagnose Hepatitis B Virus-Related Hepatocellular Carcinoma: A Large-Scale, Multicenter Study.
    Int J Cancer. 2019 Aug 28. doi: 10.1002/ijc.32647.
    >> Share

    July 2019
  56. HAN J, Han ML, Xing H, Li ZL, et al
    Tissue and serum metabolomic phenotyping for diagnosis and prognosis of hepatocellular carcinoma.
    Int J Cancer. 2019 Jul 30. doi: 10.1002/ijc.32599.
    >> Share

  57. HU B, Li H, Guo W, Sun YF, et al
    Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification.
    Int J Cancer. 2019 Jul 16. doi: 10.1002/ijc.32564.
    >> Share

  58. ZHOU Y, Li Y, Xu S, Lu J, et al
    Eukaryotic elongation factor 2 kinase promotes angiogenesis in hepatocellular carcinoma via PI3K/Akt and STAT3.
    Int J Cancer. 2019 Jul 8. doi: 10.1002/ijc.32560.
    >> Share

    June 2019
  59. CASTVEN D, Becker D, Czauderna C, Wilhelm D, et al
    Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification.
    Int J Cancer. 2019;144:2782-2794.
    >> Share

    May 2019
  60. YANG W, Sui J, Ma Y, Simon TG, et al
    A prospective study of dairy product intake and the risk of hepatocellular carcinoma in U.S. men and women.
    Int J Cancer. 2019 May 22. doi: 10.1002/ijc.32423.
    >> Share

  61. YANG Y, Chen Q, Piao HY, Wang B, et al
    HNRNPAB-regulated lncRNA-ELF209 inhibits the malignancy of hepatocellular carcinoma.
    Int J Cancer. 2019 May 15. doi: 10.1002/ijc.32409.
    >> Share

  62. JIANG T, Chu Q, Wang H, Zhou F, et al
    EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
    Int J Cancer. 2019;144:2605-2612.
    >> Share

  63. YIN S, Qiu Y, Jin C, Wang R, et al
    7-deoxynarciclasine shows promising antitumor efficacy by targeting Akt against hepatocellular carcinoma.
    Int J Cancer. 2019 May 13. doi: 10.1002/ijc.32395.
    >> Share

  64. BAO C, Yang R, Pedersen NL, Xu W, et al
    Overweight in midlife and risk of cancer in late life: A nationwide Swedish twin study.
    Int J Cancer. 2019;144:2128-2134.
    >> Share

    April 2019
  65. IIDA N, Mizukoshi E, Yamashita T, Terashima T, et al
    Overuse of anti-anaerobic drug is associated with poor post-chemotherapy prognosis of patients with hepatocellular carcinoma.
    Int J Cancer. 2019 Apr 13. doi: 10.1002/ijc.32339.
    >> Share

  66. YANG P, Huang X, Lai C, Li L, et al
    SET domain containing 1B gene (SETD1B) is mutated in primary hepatic neuroendocrine tumors.
    Int J Cancer. 2019 Apr 11. doi: 10.1002/ijc.32334.
    >> Share

  67. GE Z, Feng Y, Sheh A, Muthupalani S, et al
    Mutagenicity of Helicobacter hepaticus infection in the lower bowel mucosa of 129/SvEv Rag2(-/-) Il10(-/-) gpt delta mice is influenced by sex.
    Int J Cancer. 2019 Apr 11. doi: 10.1002/ijc.32332.
    >> Share

    March 2019
  68. TAN HW, Leung CO, Chan KK, Ho DW, et al
    Deregulated GATA6 modulates stem cell-like properties and metabolic phenotype in hepatocellular carcinoma.
    Int J Cancer. 2019 Mar 4. doi: 10.1002/ijc.32248.
    >> Share

    February 2019
  69. VAN BEEK AA, Zhou G, Doukas M, Boor PPC, et al
    GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.
    Int J Cancer. 2019 Feb 4. doi: 10.1002/ijc.32181.
    >> Share

    January 2019
  70. WANG Y, Tan PY, Handoko YA, Sekar K, et al
    NUF2 is a valuable prognostic biomarker to predict early recurrence of hepatocellular carcinoma after surgical resection.
    Int J Cancer. 2019 Jan 17. doi: 10.1002/ijc.32134.
    >> Share

  71. SANCHEZ-MEJIAS A, Kwon J, Chew XH, Siemens A, et al
    A novel SOCS5/miR-18/miR-25 axis promotes tumorigenesis in liver cancer.
    Int J Cancer. 2019;144:311-321.
    >> Share

  72. DU Y, Song W, Chen J, Chen H, et al
    The potassium channel KCa3.1 promotes cell proliferation by activating SKP2 and metastasis through the EMT pathway in hepatocellular carcinoma.
    Int J Cancer. 2019 Jan 10. doi: 10.1002/ijc.32121.
    >> Share

  73. DEVAUD C, Tilkin-Mariame AF, Vignolle-Vidoni A, Souleres P, et al
    FAK alternative splice mRNA variants expression pattern in colorectal cancer.
    Int J Cancer. 2019 Jan 10. doi: 10.1002/ijc.32120.
    >> Share

    November 2018
  74. AUGELLO G, Emma MR, Cusimano A, Azzolina A, et al
    Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma.
    Int J Cancer. 2018 Nov 29. doi: 10.1002/ijc.31963.
    >> Share

  75. LIN YT, Chen JS, Liao WY, Ho CC, et al
    Clinical Outcomes and Secondary Epidermal Growth Factor Receptor (EGFR) T790M Mutation among First-line Gefitinib, Erlotinib and Afatinib-treated Non-small Cell Lung Cancer Patients with Activating EGFR Mutations.
    Int J Cancer. 2018 Nov 28. doi: 10.1002/ijc.32025.
    >> Share

  76. FANG AP, Chen PY, Wang XY, Liu ZY, et al
    Serum Copper and Zinc levels at Diagnosis and Hepatocellular Carcinoma Survival in the Guangdong Liver Cancer Cohort.
    Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31991.
    >> Share

  77. SHENG Y, Wei J, Zhang Y, Gao X, et al
    Mutated EPHA2 is a target for combating lymphatic metastasis in intrahepatic cholangiocarcinoma.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31979.
    >> Share

  78. CHEN VC, Chan HL, Hsu TC, Lu ML, et al
    New use for old drugs: the protective effect of atypical antipsychotics on hepatocellular carcinoma.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31980.
    >> Share

    October 2018
  79. LEE YR, Kim G, Tak WY, Jang SY, et al
    Circulating exosomal non-coding RNAs as prognostic biomarkers in human hepatocellular carcinoma.
    Int J Cancer. 2018 Oct 19. doi: 10.1002/ijc.31931.
    >> Share

  80. MA X, Tan YT, Yang Y, Gao J, et al
    Pre-diagnostic urinary 15-F2t -isoprostane level and liver cancer risk: Results from the Shanghai Women's and Men's Health Studies.
    Int J Cancer. 2018;143:1896-1903.
    >> Share

  81. ABDUL-WAHID A, Cydzik M, Fischer NW, Prodeus A, et al
    Serum-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cells.
    Int J Cancer. 2018;143:1963-1977.
    >> Share

  82. YANG J, Trepo E, Nahon P, Cao Q, et al
    PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases.
    Int J Cancer. 2018 Oct 5. doi: 10.1002/ijc.31910.
    >> Share

    September 2018
  83. LEE JH
    Analysis of The Cancer Genome Atlas data to determine the correlation between PROX1 and TERT in hepatocellular carcinoma.
    Int J Cancer. 2018 Sep 24. doi: 10.1002/ijc.31888.
    >> Share

  84. CHEN G, Cai Z, Li Z, Dong X, et al
    Clonal evolution in long-term follow-up patients with hepatocellular carcinoma.
    Int J Cancer. 2018 Sep 5. doi: 10.1002/ijc.31844.
    >> Share

    August 2018
  85. MCGEE EE, Castro FA, Engels EA, Freedman ND, et al
    Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults.
    Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31835.
    >> Share

  86. MARTINEZ-CARDONA C, Lozano-Ruiz B, Bachiller V, Peiro G, et al
    AIM2 deficiency reduces the development of hepatocellular carcinoma in mice.
    Int J Cancer. 2018 Aug 22. doi: 10.1002/ijc.31827.
    >> Share

  87. WAN J, Liu H, Yang L, Ma L, et al
    JMJD6 promotes hepatocellular carcinoma carcinogenesis by targeting CDK4.
    Int J Cancer. 2018 Aug 19. doi: 10.1002/ijc.31816.
    >> Share

  88. BAO C, Pedersen NL, Yang R, Marseglia A, et al
    Diabetes in midlife and risk of cancer in late life: A nationwide Swedish twin study.
    Int J Cancer. 2018;143:793-800.
    >> Share

    July 2018
  89. KIM YJ, Yoo JE, Jeon Y, Uk Chong J, et al
    Suppression of PROX1-mediated TERT expression in hepatitis B viral hepatocellular carcinoma.
    Int J Cancer. 2018 Jul 10. doi: 10.1002/ijc.31731.
    >> Share

    June 2018
  90. BOYSEN AK, Spindler KL, Hoyer M, Mortensen FV, et al
    Metastasis directed therapy for liver and lung metastases from colorectal cancer - a population based study.
    Int J Cancer. 2018 Jun 19. doi: 10.1002/ijc.31626.
    >> Share

  91. ARAI J, Goto K, Tanoue Y, Ito S, et al
    Enzymatic inhibition of MICA sheddase ADAM17 by lomofungin in hepatocellular carcinoma cells.
    Int J Cancer. 2018 Jun 6. doi: 10.1002/ijc.31615.
    >> Share

    May 2018
  92. OH E, Kim YJ, An H, Sung D, et al
    Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
    Int J Cancer. 2018 May 9. doi: 10.1002/ijc.31585.
    >> Share

    April 2018
  93. LIU Y, De Keyzer F, Wang Y, Wang F, et al
    The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats.
    Int J Cancer. 2018 Apr 29. doi: 10.1002/ijc.31567.
    >> Share

  94. CHEN CJ, Yang YH, Lin MH, Lee CP, et al
    Herbal Medicine Containing Aristolochic Acid and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus Infection.
    Int J Cancer. 2018 Apr 18. doi: 10.1002/ijc.31544.
    >> Share

  95. KAJI K, Nishimura N, Seki K, Sato S, et al
    Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
    Int J Cancer. 2018;142:1712-1722.
    >> Share

    March 2018
  96. LI X, Guo X, Li D, Du X, et al
    Multi-regional Sequencing Reveals Intratumor Heterogeneity and Positive Selection of Somatic mtDNA Mutations in Hepatocellular Carcinoma and Colorectal Cancer.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31395.
    >> Share

  97. JAQUET A, Tchounga B, Tanon A, Bagny A, et al
    Etiology of hepatocellular carcinoma in West Africa, a case-control study.
    Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31393.
    >> Share

    February 2018
  98. MARQUEZ J, Fernandez-Pineiro I, Arauzo-Bravo MJ, Poschmann G, et al
    Targeting liver sinusoidal endothelial cells with miR-20a-loaded nanoparticles reduces murine colon cancer metastasis to the liver.
    Int J Cancer. 2018 Feb 28. doi: 10.1002/ijc.31343.
    >> Share

  99. PULTE D, Weberpals J, Schroder CC, Emrich K, et al
    Survival of patients with hepatobiliary tract and duodenal cancer sites in Germany and the United States in the early 21(st) century.
    Int J Cancer. 2018 Feb 26. doi: 10.1002/ijc.31322.
    >> Share

  100. BONNESEN TG, Winther JF, Andersen KK, Asdahl PH, et al
    Liver diseases in Adult Life after Childhood Cancer in Scandinavia (ALiCCS): A population-based cohort study of 32,839 one-year survivors.
    Int J Cancer. 2018;142:702-708.
    >> Share

    December 2017
  101. CHANG CJ, Yang YH, Chiu CJ, Lu LC, et al
    Targeting tumor-infiltrating Ly6G(+) myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma.
    Int J Cancer. 2017 Dec 20. doi: 10.1002/ijc.31216.
    >> Share

    November 2017
  102. SATTERFIELD L, Shuck R, Kurenbekova L, Allen-Rhoades W, et al
    miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma.
    Int J Cancer. 2017;141:2062-2075.
    >> Share

    October 2017
  103. HOLCH JW, Ricard I, Stintzing S, Fischer von Weikersthal L, et al
    Relevance of liver-limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE-3/AIO KRK0306 trial.
    Int J Cancer. 2017 Oct 19. doi: 10.1002/ijc.31114.
    >> Share

  104. PAN R, Zhu M, Yu C, Lv J, et al
    Cancer incidence and mortality: A cohort study in China, 2008-2013.
    Int J Cancer. 2017;141:1315-1323.
    >> Share

    September 2017
  105. JIANG W, Shen Y, Ding Y, Ye C, et al
    A naive Bayes algorithm for tissue origin diagnosis (TOD-Bayes) of synchronous multifocal tumors in the hepatobiliary and pancreatic system.
    Int J Cancer. 2017 Sep 16. doi: 10.1002/ijc.31054.
    >> Share

  106. WANG W, Xiao X, Chen X, Huo Y, et al
    Tumor-suppressive miR-145 co-repressed by TCF4-beta-catenin and PRC2 complexes forms double-negative regulation loops with its negative regulators in colorectal cancer.
    Int J Cancer. 2017 Sep 16. doi: 10.1002/ijc.31056.
    >> Share

  107. SONG IJ, Yang YM, Inokuchi-Shimizu S, Roh YS, et al
    The Contribution of Toll-Like Receptor Signaling to the Development of Liver Fibrosis and Cancer in Hepatocyte-Specific TAK1-Deleted Mice.
    Int J Cancer. 2017 Sep 5. doi: 10.1002/ijc.31029.
    >> Share

    August 2017
  108. LI S, Dai W, Mo W, Li J, et al
    By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
    Int J Cancer. 2017 Aug 31. doi: 10.1002/ijc.31022.
    >> Share

  109. DENG H, Eckel SP, Liu L, Lurmann FW, et al
    Particulate matter air pollution and liver cancer survival.
    Int J Cancer. 2017;141:744-749.
    >> Share

    July 2017
  110. YANG B, Petrick JL, Kelly SP, Graubard BI, et al
    Adiposity across the adult life course and incidence of primary liver cancer: The NIH-AARP cohort.
    Int J Cancer. 2017;141:271-278.
    >> Share

    June 2017
  111. LIN B, Zhu M, Wang W, Li W, et al
    Structural basis for alpha fetoprotein-mediated inhibition of caspase-3 activity in hepatocellular carcinoma cells.
    Int J Cancer. 2017 Jun 27. doi: 10.1002/ijc.30850.
    >> Share

  112. ZHANG Q, Yuan XF, Lu Y, Li ZZ, et al
    Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells.
    Int J Cancer. 2017 Jun 23. doi: 10.1002/ijc.30846.
    >> Share

  113. SHI H, Fang W, Liu M, Fu D, et al
    Complement component 1, q subcomponent binding protein (C1QBP) in lipid rafts mediates hepatic metastasis of pancreatic cancer by regulating IGF-1/IGF-1R signaling.
    Int J Cancer. 2017 Jun 12. doi: 10.1002/ijc.30831.
    >> Share

  114. WANG K, Nie X, Rong Z, Fan T, et al
    B lymphocytes repress hepatic tumorigenesis but not development in Hras12V transgenic mice.
    Int J Cancer. 2017 Jun 5. doi: 10.1002/ijc.30823.
    >> Share

  115. NDERITU P, Bosco C, Garmo H, Holmberg L, et al
    The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: a study in the Swedish AMORIS cohort.
    Int J Cancer. 2017 Jun 2. doi: 10.1002/ijc.30818.
    >> Share

  116. MTEYREK A, Filipski E, Guettier C, Oklejewicz M, et al
    Critical cholangiocarcinogenesis control by cryptochrome clock genes.
    Int J Cancer. 2017;140:2473-2483.
    >> Share

    May 2017
  117. SHOJI H, Yoshio S, Mano Y, Doi H, et al
    Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma.
    Int J Cancer. 2017 May 27. doi: 10.1002/ijc.30804.
    >> Share

  118. CAI ZX, Chen G, Zeng YY, Dong XQ, et al
    Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma.
    Int J Cancer. 2017 May 22. doi: 10.1002/ijc.30798.
    >> Share

  119. CHU YJ, Yang HI, Wu HC, Liu J, et al
    Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers.
    Int J Cancer. 2017 May 16. doi: 10.1002/ijc.30782.
    >> Share

  120. LEE TY, Wu JC, Yu SH, Lin JT, et al
    The occurrence of hepatocellular carcinoma in different risk stratifications of clinically non-cirrhotic non-alcoholic fatty liver disease.
    Int J Cancer. 2017 May 16. doi: 10.1002/ijc.30784.
    >> Share

    April 2017
  121. ZHANG R, Real CI, Liu C, Baba HA, et al
    Hepatic expression of oncogenes Bmi1 and Dkk1 is up-regulated in hepatitis B virus surface antigen-transgenic mice and can be induced by treatment with HBV particles or lipopolysaccharides in vitro.
    Int J Cancer. 2017 Apr 17. doi: 10.1002/ijc.30742.
    >> Share

  122. GOWING SD, Chow SC, Cools-Lartigue JJ, Chen CB, et al
    Gram-Positive Pneumonia Augments Non-Small Cell Lung Cancer Metastasis Via Host Toll-like Receptor 2 Activation.
    Int J Cancer. 2017 Apr 12. doi: 10.1002/ijc.30734.
    >> Share

  123. KE Y, Bao T, Zhou Q, Wang Y, et al
    Discs large homolog 5 decreases formation and function of invadopodia in human hepatocellular carcinoma via Girdin and Tks5: Dlg5 regulates HCC invadopodia.
    Int J Cancer. 2017 Apr 8. doi: 10.1002/ijc.30730.
    >> Share

    March 2017
  124. ZHU M, Li W, Lu Y, Dong X, et al
    HBx drives alpha fetoprotein expression to promote initiation of liver cancer stem cells through activating PI3K/AKT signal pathway.
    Int J Cancer. 2017;140:1346-1355.
    >> Share

  125. MA X, Yang Y, Li HL, Zheng W, et al
    Dietary trace element intake and liver cancer risk: Results from two population-based cohorts in China.
    Int J Cancer. 2017;140:1050-1059.
    >> Share

    February 2017
  126. ZHANG D, Zhao L, Shen Q, Lv Q, et al
    Down-regulation of KIAA1199/CEMIP by miR-216a suppresses tumor invasion and metastasis in colorectal cancer.
    Int J Cancer. 2017 Feb 18. doi: 10.1002/ijc.30656.
    >> Share

  127. XU J, Lin H, Li G, Sun Y, et al
    Sorafenib with ASC-J9(R) synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals.
    Int J Cancer. 2017;140:705-717.
    >> Share

    January 2017
  128. WANG W, Bai W, Wang E, Zhao Y, et al
    mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
    Int J Cancer. 2017;140:390-399.
    >> Share

    August 2016
  129. ZHAO Y, Li H, Bai W, Liu J, et al
    Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.
    Int J Cancer. 2016;139:928-37.
    >> Share

  130. HASHIMOTO M, Kobayashi T, Tashiro H, Arihiro K, et al
    h-Prune is associated with poor prognosis and epithelial-mesenchymal transition in patients with colorectal liver metastases.
    Int J Cancer. 2016;139:812-23.
    >> Share

  131. KURAHARA H, Bohl C, Natsugoe S, Nishizono Y, et al
    Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome-wide shRNA screen.
    Int J Cancer. 2016;139:628-38.
    >> Share

    July 2016
  132. JARY M, Lecomte T, Bouche O, Kim S, et al
    Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: A simple biological score.
    Int J Cancer. 2016 Jul 29. doi: 10.1002/ijc.30367.
    >> Share

    March 2016
  133. LOES IM, Immervoll H, Sorbye H, Angelsen JH, et al
    Impact of KRAS, BRAF, PIK3CA, TP53 status and intra-individual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
    Int J Cancer. 2016 Mar 16. doi: 10.1002/ijc.30089.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016